News & Updates
Filter by Specialty:
How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?
Combination therapy does not appear to have beneficial effects in terms of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and incidence of adverse events compared with monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) who failed first-line treatment with an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, a study has shown.
How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?
05 Dec 2023
HPV self-sampling with isothermal amplification detection may become part of cervical cancer screening
A prospective study in women attending a colposcopy clinic in Hong Kong supports the use of self-sampling with an isothermal amplification (AmpFire)–based assay for human papillomavirus (HPV) detection in cervical cancer screening, showing substantial agreement with clinician sampling using either the AmpFire-based or polymerase chain reaction (PCR)–based reference assay.
HPV self-sampling with isothermal amplification detection may become part of cervical cancer screening
05 Dec 2023
HPV ctDNA testing identifies cervical cancer patients at high risk of relapse after CRT
Detection of human papilloma virus (HPV) circulating tumour DNA (ctDNA) after completion of chemoradiation therapy (CRT) is independently associated with inferior progression-free survival (PFS) in patients with cervical cancer, a prospective multicentre study has shown. According to the researchers, early HPV ctDNA testing after CRT can identify patients at high risk of relapse.
HPV ctDNA testing identifies cervical cancer patients at high risk of relapse after CRT
05 Dec 2023
Endoscopic ultrasound-guided CPN effective for abdominal pain in pancreatic cancer
Endoscopic ultrasound-guided celiac plexus neurolysis added to medical management (EUS-CPN+MM) provides beneficial effects for abdominal pain in patients with unresectable pancreatic cancer at 4 and 12 weeks, reports a recent study.